To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Ref Type Abstract
PMID
Authors V. Gounant, L. Greillier, C. Mascaux, F. Pinquie, D. Carmier, L. Moreau, B. Roch, D. Debieuvre, X. Dhalluin, E. Giroux-Leprieur, E. Berton, A. Rabeau, J. Raimbourg, A. Dixmier, C. Naltet, A. Khalil, L. Ezzeddine, A. Langlais, F. Morin, M. Duruisseaux
Title 1324P Durvalumab in treatment-naive, stage IV non-small cell lung cancer (NSCLC) patients (pts), with ECOG performance status (PS) 2-3 and high PD-L1 tumour expression: Results of IFCT-1802 SAVIMMUNE phase II trial
Journal Vol Issue Date Pages Journal Short Title
Annals of Oncology 35 Supplement 2 September 2024 S842 Ann Oncol
URL https://www.annalsofoncology.org/article/S0923-7534(24)02898-9/fulltext
Abstract Text Background PS2-3 is a prognostic factor associated with poor survival and higher incidence of chemotherapy-related adverse events (AE), while the impact of poor PS on immunotherapy (IO) safety and efficacy is less documented. We sought to prospectively assess front-line durvalumab in PS2-3 pts with advanced NSCLC and high PD-L1 expression. Methods In this single-arm, multicenter, phase II trial, PS2-3 pts with metastatic ALK-/EGFRwt NSCLC, PD-L1 positive (TPS ≥25%), without brain metastases, received 1500 mg durvalumab every 4 weeks until progression or toxicity. Primary endpoint was safety defined as the incidence of grade ≥3 treatment-related AE (TRAE) during the first 8 weeks (NCI CTCAE v.5.0). Using a 2-step binomial proportion test (O’Brien-Fleming’s procedure), 67 pts were to be included, to achieve 95% power, with 5% type I error rate, to observe <40% (H0) G3-5 events. Secondary objectives included intent-to-treat blinded independent centrally reviewed (BICR) objective response rate (ORR) and progression-free survival (PFS), median duration of response (DoR), overall survival (OS) and PS improvement at 8 weeks. Results Overall, 50 pts (median age 68 yrs, PS2 n=40; PS3 n=10) were enrolled between Oct 2020 and Jul 2023. The trial was stopped due to slow accrual. Median follow-up was 15.7 months. Median number of cycles was 3 (1-26). Grade ≥3 TRAE during the first 8 weeks occurred in 10% of pts (95% CI 1.7%–18.3%). No grade 5 TRAE were reported. BICR ORR at 8 weeks (partial responses only) was 26% (95% CI 13.8%–38.2%) and 24% (95% CI 12.2%–35.8%) were confirmed at 16 weeks. Median DoR was 11.3 months (95% CI, 6.4 to NR). Median PFS was 2.3 months (95% CI 1.7–5.6). Median OS was 6.9 months (95% CI 3.9–31.1) with a 40% (95% CI 26. 1–53.7) 12-month OS rate. Median OS in PS2 pts was 9.7 months (95% CI 4.4-NR) and in PS3 pts was 3.0 months (95% CI 0.2-5.6). 12 (44%) of 27 pts with evaluable PS at 8 weeks of durvalumab treatment (95% CI, 25.7%-63.2%) had improved PS (p= 0.01). Conclusions In PS2-3 pts with advanced NSCLC and high PD-L1 expression (TPS ≥25%), front-line durvalumab is safe and showed interesting activity. Patient Reported Outcomes will be presented at the meeting. Clinical trial identification EudraCT 2018-004742-42.

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
CD274 positive lung non-small cell carcinoma predicted - sensitive Durvalumab Phase II Actionable In a Phase II trial (SAVIMMUNE), Imfinzi (durvalumab) treatment demonstrated safety and resulted in an 8-week objective response rate (ORR) of 26%, and 16-week ORR of 24%, median progression-free survival of 2.3 months, median overall survival (OS) of 6.9 months, a 12-month OS rate of 40%, and a median duration of response of 11.3 months in patients with advanced CD274 (PD-L1)-positive (TPS >/=25%) non-small cell lung cancer with a performance score of 2 or 3 (Ann Oncol (2024) 35 (suppl_2): S842). detail...